首页> 外文期刊>International journal of biological sciences >PKD knockdown inhibits pressure overload-induced cardiac hypertrophy by promoting autophagy via AKT/mTOR pathway
【24h】

PKD knockdown inhibits pressure overload-induced cardiac hypertrophy by promoting autophagy via AKT/mTOR pathway

机译:PKD抑制通过通过AKT / mTOR途径促进自噬来抑制压力超负荷引起的心脏肥大

获取原文
           

摘要

Growing evidence shows that protein kinase D (PKD) plays an important role in the development of pressure overload-induced cardiac hypertrophy. However, the mechanisms involved are not clear. This study tested our hypothesis that PKD might mediate cardiac hypertrophy by negatively regulating autophagy using the technique of PKD knockdown by siRNA. Cardiac hypertrophy was induced in 8-week old male C57BL/6 mice by transverse aortic constriction (TAC). TAC mice were then divided into five groups receiving the treatments of vehicle (DMSO), an autophagy inducer rapamycin (1 mg/kg/day, i.p.), control siRNA, lentiviral PKD siRNA (2×108 transducing units/0.1 ml, i.v. injection in one day after surgery, and repeated in 2 weeks after surgery), and PKD siRNA plus 3-methyladenine (3-MA, an autophagy inhibitor, 20 mg/kg/day, i.p.), respectively. Four weeks after TAC surgery, echocardiographic study, hematoxylin and eosin (HE) staining, and Masson's staining showed mice with TAC had significantly hypertrophy and remodeling compared with sham animals. Treatments with PKD siRNA or rapamycin significantly ameliorated the cardiac hypertrophy and dysfunction. Moreover, PKD siRNA increased cardiac autophagic activity determined by electron micrographic study and the biomarkers by Western blot, accompanied with the downregulated AKT/mTOR/S6K signaling pathway. All the cardiac effects of PDK knockdown were inhibited by co-treatment with 3-MA. These results suggest that PKD is involved in the development of cardiac hypertrophy by inhibiting cardiac autophagy via AKT/mTOR pathway.
机译:越来越多的证据表明,蛋白激酶D(PKD)在压力超负荷引起的心脏肥大的发展中起重要作用。但是,涉及的机制尚不清楚。这项研究检验了我们的假设,即PKD可能通过使用siRNA抑制PKD的技术通过负调控自噬来介导心脏肥大。在8周龄的雄性C57BL / 6小鼠中,通过横向主动脉缩窄(TAC)诱发心脏肥大。然后将TAC小鼠分为五组,分别接受媒介物(DMSO),自噬诱导剂雷帕霉素(1 mg / kg / day,ip),对照siRNA,慢病毒PKD siRNA(2×10 8 转导单位/0.1 ml,分别在术后一天静脉注射和术后2周重复注射)和PKD siRNA加3-甲基腺嘌呤(3-MA,自噬抑制剂,20 mg / kg /天,腹腔注射) 。 TAC手术后四周,超声心动图研究,苏木精和曙红(HE)染色以及Masson染色显示,与假动物相比,患有TAC的小鼠具有明显的肥大和重塑。 PKD siRNA或雷帕霉素治疗可明显改善心脏肥大和功能障碍。此外,PKD siRNA通过电子显微照片研究确定了心脏自噬活性,通过蛋白质印迹法确定了生物标志物的活性,并伴随着AKT / mTOR / S6K信号通路的下调。与3-MA共同治疗可抑制PDK抑制的所有心脏效应。这些结果表明,PKD通过抑制经由AKT / mTOR途径的心脏自噬而参与了心脏肥大的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号